ライフサイエンスコーパス: protein p53

1 ed additionally for the tumor suppressor p53 protein (p53).

2 d and oxidized forms of the tumor suppressor protein p53.

3 V induce the degradation of tumor suppressor protein p53.

4 utations in KRAS, BRAF, or PIK3CA, and tumor protein p53.

5 one proteins, including the tumor suppressor protein p53.

6 SET8/PR-Set7 regulates the tumor suppressor protein p53.

7 criptional network of human tumor suppressor protein p53.

8 rylating and activating the tumor-suppressor protein p53.

9 in is known to regulate the tumor suppressor protein p53.

10 causes a rapid stabilization of the cellular protein p53.

11 for the proper function of tumor suppressor protein p53.

12 y rescued by removal of the tumor suppressor protein p53.

13 apoptosis downstream of the tumor-suppressor protein p53.

14 scriptional activity of the tumor suppressor protein p53.

15 hibitory cytokines and the tumour-suppressor protein p53.

16 hibitor of signaling by the tumor suppressor protein p53.

17 proline-rich domain of the tumor suppressor protein p53.

18 a checkpoint involving the tumor suppressor protein p53.

19 es and hence stabilizes the tumor suppressor protein p53.

20 crease in the expression of the proapoptotic protein p53.

21 the proapoptotic BAX is the tumor suppressor protein p53.

22 ctivity is repressed by the tumor suppressor protein p53.

23 apid elevations of the DNA damage-responsive protein p53.

24 in a complex stabilized by tumor suppressor protein p53.

25 int independently of the 'tumour suppressor' protein p53.

26 iptionally regulated by the tumor suppressor protein p53.

27 rization domain (TD) of the tumor suppressor protein p53.

28 ovarian tumor cell lines not expressing the protein p53.

29 cally disordered tetrameric tumor suppressor protein p53.

30 atures of activation of the tumor-suppressor protein p53.

31 l negative regulator of the tumor suppressor protein p53.

32 teraction with the cellular tumor suppressor protein p53.

33 rous proteins including the tumor suppressor protein p53.

34 PARgamma, NFkappaB, and the tumor suppressor protein p53.

35 TP53, the gene encoding the tumor-suppressor protein p53.

36 sion by down-regulating the tumor suppressor protein, p53.

37 to assess mutations in the tumour-suppressor protein, p53.

38 target proteins such as the tumor suppressor protein, p53.

39 scription factors including the proapoptotic protein, p53.

40 interacts directly with the tumor suppressor protein, p53.

41 scriptional activity of the tumor suppressor protein, p53.

42 s ability to bind the human tumor suppressor protein, p53.

43 sed for the presence of the tumor suppressor protein, p53.

44 The mutant protein p53(143V-->A) was inactive.

45 sulted in a frame shift and a 420 amino acid protein (p53(420)).

46 to form a complex with the tumor suppressor protein p53, a known inducer of apoptosis, thereby stabi

47 the protective role of the tumor suppressor protein p53, a nuclear phosphoprotein and transcription

48 tivity and stability of the tumor suppressor protein p53--a cellular process initiated by MDM2 and/or

49 nce of Myc, AMPK-stabilized tumor suppressor protein p53 accumulates in the mitochondria and interact

50 The principal tumour-suppressor protein, p53, accumulates in cells in response to DNA da

51 The tumor suppressor protein p53 acts as a transcription factor, binding sequ

52 inds to and inactivates the tumor suppressor protein p53, allowing efficient replication of the virus

53 The tumour suppressor protein p53 (also known as TP53) influences a range of c

54 and increased levels of the tumor suppressor protein p53 and a cell cycle inhibitor protein p21 (Waf1

55 tivity and stability of the tumor suppressor protein p53 and are important molecular targets for anti

56 th the up-regulation of the tumor suppressor protein p53 and concurrent up-regulation of the cyclin-d

57 affects the binding of the tumour suppressor protein p53 and correlates with decreased expression of

58 by decreasing levels of the tumor suppressor protein p53 and downstream target genes.

59 e in the expression of tumor suppressor gene protein p53 and elevation of the level of cyclin-depende

60 an form complexes with the tumour-suppressor protein p53 and generate high levels of reactive oxygen

61 53BP1 binds to the tumor suppressor protein p53 and has a potential role in DNA damage respo

62 The interplay between the host protein p53 and IAV, in particular through the viral non

63 the interaction between the tumor suppressor protein p53 and its negative regulators MDM2 and MDMX is

64 delivered recombinant human tumor suppressor protein p53 and its tumor-selective supervariant into ta

65 geal adenocarcinomas have mutations in tumor protein p53 and mutations that activate receptor-associa

66 ins such as annexin A2, the tumor-suppressor protein p53 and myosin IIA.

67 d to significantly increase tumor suppressor protein p53 and p53-regulated growth-related protein p21

68 3C can directly bind to the tumor suppressor protein p53 and repress its functions, in part by blocki

69 at LANA interacts with the tumour suppressor protein p53 and represses its transcriptional activity.

70 ere associated with an increase in the tumor protein p53 and the cyclin-dependent kinase inhibitor p2

71 oach was validated with the tumor suppressor protein p53 and the forkhead protein FoxI1 using genomic

72 a pathway that involves the tumor suppressor protein p53 and the mitochondrial translocation of p53.

73 ontaining target sequences in the checkpoint protein p53 and the nonsense-mediated mRNA decay (NMD) p

74 clear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human

75 y be cross talk between the tumor suppressor protein p53 and WISP-1 signaling pathways.

76 expression of the zinc-containing DNA-repair proteins p53 and apurinic endonuclease (APE).

77 protein, and up-regulated the pro-apoptotic proteins p53 and Bax.

78 As were ubiquitin, the cell cycle-regulating proteins p53 and mdm-2, HSP70, the global transcriptiona

79 nce by down-regulating senescence-associated proteins p53 and p16.

80 ning, expression of the senescent associated proteins p53 and p16INK4a, and apoptosis of CPCs, impair

81 ly downregulated, while the tumor suppressor proteins p53 and p21 were substantially upregulated foll

82 ressed SA-beta-gal and senescence-associated proteins p53 and p21(WAF1).

83 ncreased expression of senescence-associated proteins p53 and p21(WAF1/CIP1).

84 to the accumulation of the tumor suppressor proteins p53 and p21.

85 of pyridine nucleotides and tumor suppressor proteins p53 and p73, and a decrease in apoptosis.

86 -ag), which inactivates the tumor-suppressor proteins p53 and pRb family members.

87 s and was shown to bind the tumor suppressor proteins p53 and pRb.

88 art, to inactivation of the tumor suppressor proteins p53 and pRB.

89 reover, the expressions of tumour suppressor proteins p53 and PTEN were upregulated along with the do

90 rtners such as the cellular tumor suppressor proteins p53 and Rb, both in vitro and in vivo.

91 process by inactivating the tumor suppressor proteins p53 and Rb, respectively, in addition to their

92 functional activity of the tumor suppressor proteins p53 and RB.

93 part to perturbation of the tumor suppressor proteins p53 and the retinoblastoma (pRB) family members

94 d (E) abolishes interactions with its client proteins p53 and UPF1.

95 se mechanisms may also involve innate immune proteins, p53 and changes in translation.

96 the DeltaDeltaGs for two clinically relevant proteins, p53 and myoglobin, and for pathogenic and beni

97 tions with DNA binding domains of p53 family proteins, p53 and p73.

98 of somatic mutations in TP53 (encoding tumor protein p53) and PTEN (encoding phosphate and tensin hom

99 in the cell activates the tumour-suppressor protein p53, and failure of this activation leads to gen

100 ng enhanced degradation of tumour suppressor protein p53, and inhibition of gankyrin activity has the

101 residue(s) of histones, the tumor-suppressor protein p53, and splicing regulatory proteins, including

102 ional downregulation by the tumor suppressor protein p53, and this repression can be shown to contrib

103 ensus binding site for the tumour suppressor protein p53, and we show by gel-retardation analysis tha

104 We found induction of tumor suppressor protein, p53, and apoptosis with suppression of urokinas

105 IDPs, such as alpha-synuclein, tau protein, p53, and BRCA1, are attractive targets for drug

106 ell cycle, the retinoblastoma-susceptibility protein, p53, and possibly DDX5 and DDX3 lead to enhance

107 tophagy; not reliant on the tumor suppressor protein p53; and effective against mouse models for B-ce

108 nstrate that IRF-1 and the tumour suppressor protein p53 are coordinately up-regulated during the res

109 binding core domain of the tumour suppressor protein p53 are frequent in cancer.

110 Levels of the tumour suppressor protein p53 are increased in response to a variety of DN

111 trigger the induction of the stress response protein p53 are poorly understood but may involve altera

112 Here we identify the tumour-suppressor protein p53 as a COP1-interacting protein.

113 We also identified the tumor suppressor protein p53 as a mediator of podocyte apoptosis in cells

114 rogation of function of the tumor-suppressor protein p53 as a result of mutation of its gene, TP53, i

115 phosphorylation of the p53 tumor suppressor protein (p53) at serine 18, and increased p53 protein le

116 The DNA repair protein p53 binding protein 1 (53BP1) protects the genom

117 by the tandem tudor domain containing tumor protein p53 binding protein 1 (53BP1).

118 e damage-induced recombinase Rad51 and tumor protein P53 binding protein foci formation.

119 e we examine the genome-wide impact of tumor protein P53-binding protein 1 (53BP1) deficiency in lymp

120 MRN and ATM, including the tumour suppressor proteins p53-binding protein 1 (53BP1) and BRCA1.

121 proteins interact with the tumor suppressor protein p53 both in vitro and in vivo.

122 ells harboring a functional tumor suppressor protein p53, but much less efficiently in p53-null mutan

123 are thought to involve the tumor suppressor protein p53, but the degree to which this factor contrib

124 any cancers, stabilizes the tumor suppressor protein p53 by abrogating its MDM2-dependent proteasomal

125 Inactivation of the tumor suppressor protein p53 by mutagenesis, chemical modification, prote

126 Tumor suppressor protein p53 can act as a transcription factor affecting

127 Here we report that the tumor suppressor protein p53 can associate with PXR and downregulate its

128 red, activation of the cell cycle checkpoint protein p53 can lead to apoptosis.

129 rotein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and i

130 gically important residues on the checkpoint proteins p53, Chk1, and RPA.

131 tivity and stability of the tumor suppressor protein p53, conferring tumor development and survival.

132 erminal BOX-I domain of the tumor suppressor protein p53 contains the primary docking site for MDM2,

133 The tumor suppressor protein p53 contributes to the control of cell cycle che

134 ly, we show that Na and the tumor suppressor protein p53 cooperate to induce lytic gene expression in

135 Here we show that the tumor suppressor protein p53 cooperates with DNA methylation to maintain

136 The tumor suppressor protein p53 coordinates the cellular response to stress

137 mutations occurring in the tumour suppressor protein p53, demonstrating the applicability of the prop

138 nsic apoptotic pathway in a tumor suppressor protein p53-dependent manner.

139 IFN-induced protein p53 directly reduces epithelial proliferation an

140 disorder-cytochrome c, the tumor suppressor protein p53 DNA binding domain (p53 DBD), and the N-term

141 The tumor suppressor protein p53 down-regulates a number of genes, including

142 of Ku80 along with the cell cycle checkpoint protein, p53, dramatically increases the incidence of pr

143 on the conjugation of SUMO-1 with the target proteins p53, E1B, and promyelocytic leukemia protein an

144 ct that is dependent on the tumor suppressor protein p53 (encoded by Trp53 in mice) and is characteri

145 protein Myc, or loss of the tumor suppressor protein p53 (encoded by Trp53 in mice) further accelerat

146 eceptor alpha (ERalpha) and tumor suppressor protein p53 exert opposing effects on cellular prolifera

147 The tumor suppressor protein p53 exhibits high affinity to the response eleme

148 Under normal conditions, tumor suppressor protein p53 exists in the cell in its latent form and is

149 evious assumptions that the tumor suppressor protein p53 exists primarily and functionally as a singl

150 ibe the oxidation of a cell-cycle regulatory protein, p53, from a distance through DNA-mediated CT.

151 The tumor suppressor protein p53 functions as a transcriptional factor that a

152 ate dehydrogenase (GAPDH), and the recycling protein p53/gp58.

153 e that also had deletion of tumor-suppressor protein p53 (H2b/p53(DeltaIEC)); we compared phenotypes

154 -alpha, an inhibitor of the tumor suppressor protein p53, had no effect on ROS generation but did blo

155 mothripsis, and a simpler genotype, WT tumor protein p53, had relatively few SNVs (average of 5.9 per

156 The tumor suppressor protein p53 has been well documented as a transcriptiona

157 The tumour-suppressor protein p53 has then been compared with the non-redundan

158 2 (HDM2), which binds to and inactivates the protein p53, has been linked to tumor aggressiveness and

159 he roles and actions of the tumor suppressor protein p53 have been extensively studied with regard to

160 The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be

161 pidermal patches that stain positive for p53 protein (p53 immunopositive patches, PIPs), which are co

162 reast cancer cells, whereas tumor suppressor protein p53 impedes proliferation of cells with genomic

163 PA alters expression of the tumor suppressor protein p53 in Beas2B airway epithelial cells in both a

164 d to detect unlabeled human tumor suppressor protein p53 in crude lysates, without any purification s

165 Lysine acetylation of the tumor suppressor protein p53 in response to a wide variety of cellular st

166 14-3-3 sigma is induced by tumor suppressor protein p53 in response to DNA damage.

167 ription target of the human tumor-suppressor protein p53 in signaling apoptosis and growth suppressio

168 the tetramers formed by the tumor suppressor protein p53 in single living cells.

169 of evidence implicating the tumor suppressor protein p53 in terminal differentiation of the renal epi

170 d its role in anchoring the tumor suppressor protein p53 in the cytoplasm reveals yet another level o

171 Tumor protein p53-induced nuclear protein 1 (TP53INP1) is invo

172 The tumor suppressor protein p53 induces or represses the expression of a var

173 er and CCCH-type domain 1 (RC3H1), and tumor protein p53-inducible protein 11 (TP53I11) interacted wi

174 E1B-55kDa and E4orf6 to the tumor suppressor protein p53 inhibits its transcriptional activity and ca

175 The multifunctional tumor suppressor protein, p53, inhibits cell growth and promotes differen

176 biquitinate and degrade the tumor suppressor protein p53, involving interactions with the N-terminal

177 Improper function of the tumor suppressor protein p53 is a contributing factor in many human cance

178 The major tumor suppressor protein p53 is a key cell regulator involved in cell pro

179 The tumor suppressor protein p53 is a transcription factor that is frequently

180 The tumor suppressor protein p53 is a transcription factor that is mutated in

181 The tumor suppressor protein p53 is a transcription factor that regulates apo

182 The tumor suppressor protein p53 is a transcription factor that regulates the

183 Because tumor suppressor protein p53 is also a redox active transcription factor

184 M2 and MDMX to activate the tumor suppressor protein p53 is an attractive therapeutic paradigm for th

185 The tumor suppressor protein p53 is critical for cell fate decisions, includi

186 The tumor suppressor protein p53 is emerging as a central regulator of homolo

187 s study, we report that the tumor suppressor protein p53 is essential for the induction of cell death

188 he transcription factor and tumor suppressor protein p53 is frequently inactivated in human cancers.

189 The tumor suppressor protein p53 is frequently inactivated in tumors.

190 The tumor suppressor protein p53 is inactivated by mutation in about half of

191 al cellular conditions, the tumor suppressor protein p53 is kept at low levels in part due to ubiquit

192 The tumor suppressor protein p53 is known to be transported to the nucleus al

193 The tumor suppressor protein p53 is known to induce either apoptosis or growt

194 The tumour suppressor protein p53 is localized in the cell nucleus where it se

195 The tumor-suppressor protein p53 is mutated in approximately half of all canc

196 The tumor suppressor protein p53 is mutated in over half of human cancers.

197 In unstressed cells, the tumor suppressor protein p53 is present in a latent state and is maintain

198 The tumour suppressor protein p53 is stabilised and activated in response to i

199 As a key cellular regulatory protein p53 is subject to tight regulation by several E3

200 he C-terminal domain of the tumor suppressor protein p53 is the site of non-specific DNA binding.

201 The tumor-suppressor protein p53 is tightly controlled in normal cells by its

202 cells, the function of the tumor suppressor protein p53 is usually blocked.

203 As a shuttling protein, p53 is constantly transported through the nucle

204 Among such proteins, p53 is known to respond to DNA damage by accum

205 The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 1

206 fecter of this pathway, the tumor suppressor protein p53, is tightly regulated by controlled degradat

207 provides evidence that the tumor suppressor protein, p53, is a transcriptional repressor of PKD1.

208 Tumor suppressor protein, p53, is an intracellular protein that is critic

209 The tumor suppressor protein, p53, is either mutated or absent in >50% of can

210 The oncogene suppressor protein, p53, is serine phosphorylated by several kinase

211 One of these proteins, p53, is a master regulator involved in a large

212 The tumor suppressor protein p53 localizes to microtubules (MT) and, in respo

213 Because the tumor suppressor protein p53 may be involved in these effects, we have in

214 The tumor suppressor protein p53 may have other roles and functions in additi

215 Variability in the bcl-2 family of proteins, p53 mutation, or the presence of various chrom

216 All three had tumor protein p53 mutations and a relatively large number of s

217 ns in cultured cancer cells with TP53 (tumor protein p53) mutations, in cells from patients with nons

218 lly dependent inhibition of tumor suppressor protein p53, normalization of the pro-apoptotic Bax/Bcl-

219 ked hyperacetylation of the tumor suppressor protein p53 on lysine 370, 379 and 383; these post-trans

220 The tumor suppressor protein p53, once activated, can cause either cell cycle

221 uld be altered by depleting tumor suppressor protein p53 or its transcriptional target p21(CIP/WAF).

222 gnition motif of either the tumor suppressor protein p53 or the oncogenic transcription factor TAZ.

223 lls deficient in either the tumor suppressor proteins p53 or Bax, apoptosis was least affected in the

224 Moreover, knocking down tumor suppressor proteins p53 or pRB using small interfering RNA signific

225 Tumor suppressor protein p53, our most critical defense against tumorigen

226 indicated by up-regulated senescence-related proteins p53, p16, and beta-galactosidase activity.

227 of key cell cycle regulators (retinoblastoma protein, p53, p21(waf1/Cip1), and p16(INK4A)), and senes

228 onally dead variant of the tumour-suppressor protein p53 (p53(25,26,53,54)), along with a wild-type a

229 that none of the 27 patients with both tumor protein p53 (p53) and v-Ki-ras2 Kirsten rat sarcoma vira

230 ivation domain of the human tumor suppressor protein p53 (p53TAD) and the 70 kDa subunit of human rep

231 tain coat protein I (COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in

232 synthetic inhibitors of the tumor suppressor protein p53, pifithrin-alpha (PFT-alpha) and Z-1-117, ar

233 The tumor suppressor protein p53 plays a central role in modulating the cellu

234 The tumor suppressor protein p53 plays a central role in protecting normal ce

235 The tumor suppressor protein p53 plays a central role in tumor prevention.

236 Although tumor suppressor protein p53 plays a critical role in the elimination of

237 The tumor suppressor protein p53 plays a crucial role in coordinating cellula

238 The tumor suppressor protein p53 plays a key role in maintaining the genomic

239 The tumor suppressor protein p53 plays an important role in maternal reproduc

240 The tumor suppressor protein, p53, plays a critical role as a transcriptional

241 The tumor suppressor protein, p53, plays a critical role in mediating cellula

242 of their downstream target tumor suppressor proteins (p53, Rb and PTPN 13).

243 The tumor suppressor protein p53 regulates numerous signaling pathways by spe

244 The tumor suppressor protein p53 regulates transcriptional programs that cont

245 The tumor suppressor protein p53 regulates various cellular responses to DNA

246 udies revealed two unique functions for this protein: p53 regulates cellular energy metabolism and an

247 hich it cooperates with the tumor suppressor protein p53, remain poorly understood.

248 types of DNA lesions by the tumor suppressor protein, p53, represents one of the several downstream f

249 Rapid turnover of the tumor suppressor protein p53 requires the MDM2 ubiquitin ligase, and both

250 by demethylating histone and the non-histone protein p53, respectively.

251 o stressful conditions, the tumor suppressor protein p53 restrains growth by promoting an arrested ce

252 ncrease the activity of the tumor suppressor protein p53, resulting in cell cycle arrest.

253 lowed by phosphorylation of tumor suppressor protein p53 Ser 15 at 3 to 6 h p.i., stabilizing p53 lev

254 that NPCs deficient in the tumor suppressor protein p53 show significantly less death after exposure

255 y of stimuli, including the tumor suppressor protein p53, that can mediate cell cycle arrest through

256 The tumor suppressor protein p53, the "guardian of the genome", is inactivate

257 eems to form a complex with tumor suppressor protein p53, thereby enhancing its intracellular level t

258 forming a complex with the tumour-suppressor protein p53, thereby stabilizing it and enhancing its fu

259 l fibroblasts that lack the tumor-suppressor protein p53 through a paracrine mechanism.

260 large regions of the human tumor suppressor protein p53 to identify single amino-acid substitutions

261 The ability of the tumor suppressor protein, p53, to recognize certain types of DNA lesions

262 Mutations in the tumor protein p53 (TP53) are the most frequently occurring gen

263 the effects for SNP309 and the related tumor protein p53 (TP53) Arg72Pro are inconsistent among publi

264 omosomal networking protein (CTCF) and tumor protein p53 (TP53) bind to TP73 promoter and regulate TP

265 mon mutations in the TERT promoter and tumor protein P53 (TP53) coding region were analyzed in 101 HB

266 Tumor protein p53 (TP53) is the most frequently mutated gene i

267 ma viral oncogene homolog B (BRAF) and tumor protein p53 (TP53) mutations cooccur in a high proportio

268 arcomatoid elements acquired biallelic tumor protein p53 (TP53) mutations in 32% of tumors (P = 5.47

269 cancers, TDP tumors conjointly exhibit tumor protein p53 (TP53) mutations, disruption of breast cance

270 d at 17p13, only 500-kb centromeric of tumor protein p53 (Tp53), and is codeleted with Tp53, we propo

271 emonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncoge

272 DNA damage transactivates tumour protein p53 (TP53)-regulated surveillance, crucial in su

273 he expression of the mutant tumor suppressor protein p53 (Tp53).

274 primary mouse epithelial cells lacking tumor protein p53 (TP53, best known as p53) in the presence of

275 TNBC has a high frequency of tumor protein p53 (Tp53/p53)- and phosphatase and tensin homol

276 ating cell nuclear antigen, tumor suppressor protein p53, transcription factor NF-kappaB p50 and its

277 with somatic loss of transformation-related protein p53 (Trp53) function and/or overexpression of hu

278 as human epidermal growth factor receptor 2 protein, p53 tumor suppressor gene, Ki-67 proliferation

279 at, together with a variety of other nuclear proteins, p53 undergoes extensive poly(ADP-ribosyl)ation

280 ed expression of Bcl-2 homology 3 (BH3)-only protein p53 up-regulated modulator of apoptosis (PUMA),

281 vels of p53 and the p53-related proapoptotic proteins p53-up-regulated modulator of apoptosis (PUMA)

282 mulation and acetylation of tumor suppressor protein p53 upon the cell cycle entry of hair follicle e

283 The Bcl homology-3 (BH3)-only protein p53 upregulated modulator of apoptosis (PUMA) co

284 ently showed a critical role of the BH3-only protein p53 upregulated modulator of apoptosis (PUMA) in

285 heckpoint protein p21, but not the apoptotic protein p53-upregulated modulator of apoptosis.

286 ng degradation of the pro-apoptotic BH3-only protein p53-upregulated modulator of apoptosis.

287 ondrial dysfunction and the tumor suppressor protein p53 using a set of respiration-deficient (Res(-)

288 The tumor suppressor protein, p53, utilizes multiple mechanisms to ensure fai

289 type activation of temperature-sensitive p53 protein (p53 val) at permissive temperature in M1-t-p53

290 lation of the pro-apoptotic tumor suppressor protein, p53, via PKB-mediated phosphorylation of MDM2 m

291 he intrinsically disordered tumor suppressor protein p53 was analyzed by using a combination of ion m

292 Protein p53 was determined using an enzyme-linked immuno

293 ound that expression of the tumor suppressor protein p53 was higher in MCH(-/-) mice at 9 and 19 mont

294 t negative regulator of the tumor suppressor protein p53 which regulates the expression of many genes

295 negative regulators of the tumor suppressor protein p53, which are frequently upregulated in cancer

296 poptosis independent of the tumor suppressor protein p53, which primarily affects DNA damage-induced

297 cytomegalovirus (HCMV), the tumor suppressor protein p53, which promotes efficient viral gene express

298 ntified a hitherto-unknown FBXW7-interacting protein, p53, which is phosphorylated by glycogen syntha

299 ported as activators of the tumor suppressor protein p53 with therapeutic potential.

300 a rapid accumulation of the tumor-suppressor protein p53 within target cells, which seems to be invol